Alta Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Alta Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-557	Closed	-$221K	–	208
2025 Q4	$221K	Sell	557 -200	-26%	-$88.5K	0.08%	177
2025 Q3	$345K	Hold	757	–	–	0.11%	158
2025 Q2	$247K	Hold	757	–	–	0.09%	199
2025 Q1	$204K	Buy	+757	New	+$195K	0.09%	224
2024 Q4	–	Sell	-400	Closed	-$110K	–	164
2024 Q3	$110K	Hold	400	–	–	0.05%	273
2024 Q2	$97.2K	Hold	400	–	–	0.05%	269
2024 Q1	$59.8K	Hold	400	–	–	0.03%	369
2023 Q4	$76.6K	Hold	400	–	–	0.04%	315
2023 Q3	$70.8K	Hold	400	–	–	0.04%	310
2023 Q2	$76K	Hold	400	–	–	0.04%	311
2023 Q1	$80.1K	Hold	400	–	–	0.05%	293
2022 Q4	$95K	Hold	400	–	–	0.06%	237
2022 Q3	$80K	Buy	+400	New	+$76.3K	0.05%	258

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alta Advisers's ALNY Position: Q1 2026 in Review

Alta Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 557 shares — an estimated $221K sold.

Alta Advisers first reported a position in ALNY in Q3 2022 and held it in 13 quarters. The position peaked at $345K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Alta Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Alta Advisers sold 557 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $221K.
Alta Advisers first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 13 quarters.
Alta Advisers's Alnylam Pharmaceuticals position peaked at $345K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Alta Advisers's 13F filing for Q1 2026, filed 7 May 2026.